Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2025

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

The assets and liabilities of AxoBio as of March 26, 2024 consisted of the following:

Assets available for sale
Cash and cash equivalents	$	30,001
Accounts receivable, net		4,495,200
Prepaid expenses		219,303
Inventories		3,036,107
Property and equipment, net		52,556
Intangible assets, net		21,636,947
Goodwill		19,188,278
Total assets available for sale	$	48,658,392
Liabilities available for sale
Accounts payable	$	6,612,869
Accrued interest		122,673
Accrued interest, related party		89,448
Other accrued expenses		72,581
Loans payable		1,509,312
Related party loans		5,610,000
Deferred consideration payable		8,000,000
Deferred income taxes		5,380,830
Total liabilities available for sale	$	27,397,713

The significant components of discontinued operations for the six months ended June 30, 2024 in the accompanying unaudited condensed consolidated statements of income are as follows:

Operating expenses:
Selling and marketing	$	100,000
Research and development		89,972
General and administrative		470,686
Depreciation and amortization		636,449
Total operating expenses		1,297,107
Loss from operations		(1,297,107	)
Other income (expense):
Amortization of debt discount		(4,242	)
Interest expense, related party		(89,448	)
Interest expense		(17,571	)
Total other (expense) income		(111,261	)
Loss before income taxes		(1,408,368	)
Income tax benefit, deferred		156,092
Discontinued operations, net	$	(1,252,276	)